Reading LFMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LFMD free→Reading LFMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LFMD free→NASDAQHealth CareHealth Information ServicesSnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak. Earnings quality cannot be assessed since the company is unprofitable. Management's recent track record has been unsteady. Risk is elevated, and the sector backdrop is a headwind. Compared with sector peers, LFMD trades below typical levels. Peer multiples imply a price about 69% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk. This pattern often occurs when financials are weak or earnings quality is fragile. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $4.91. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $4.91 LFMD trades at 2× p/s, in line with its 2× p/s peer median. Our $15 fair value reflects that, medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 68% below a flat-multiple fair value, below our forecast of about 27%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted -0.28x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to long-term interest rates, Fed net liquidity, the US dollar, real (inflation-adjusted) rates.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.01 → $-0.04 (-400.0% / 30d). 0 raised, 1 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 100% of analysts rate Buy.
1 PT revisions / 30d. Avg target 135.8% above current price.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$280.
How much price usually moves either way.
On a bad day, this stock has moved -$701.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $8,247.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for LFMD yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 6, 2026, LifeMD, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Roughly priced in line with peers.
Self-history needs ~20 months of data.
Trailing four: 2017-Q2, 2017-Q3, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Technology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
LFMD LifeMD, Inc. | Below typical Show detailsSector percentile: 6 of 100 | inexpensive | elevated |
VEEV Veeva Systems | Above typical Show detailsSector percentile: 78 of 100 | full | elevated |
SOLV Solventum | Above typical Show detailsSector percentile: 73 of 100 | fair | moderate |
TEM TEMPUS AI, INC. | Above typical Show detailsSector percentile: 72 of 100 | — | elevated |
DOCS Doximity | Above typical Show detailsSector percentile: 80 of 100 | full | high |
10 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
LifeMD aims to achieve revenue growth within the range of $220 million to $230 million for the fiscal year 2026.
Stated in 3 of last 3 quarters. Revenue grew from $20.3M in 2025-Q4 to $50.2M in 2026-Q1, showing significant progress towards the $220M-$230M target for 2026. The trajectory indicates delivering on the growth priority.
“The Company affirms its previously issued guidance: Revenue in the range of $220 million to $230 million.”
“For the full year 2026, the Company expects: Revenue in the range of $220 million to $230 million.”
“For the full year 2025, the Company’s guidance reflects revenue...: Revenue in the range of $192 million to $193 million.”
LifeMD targets adjusted EBITDA in the range of $12 million to $17 million for the fiscal year 2026.
Stated in 3 of last 3 quarters. While the adjusted EBITDA target for 2026 is set between $12M and $17M, the financials do not provide specific EBITDA figures for comparison. The trajectory remains unclear due to lack of detailed EBITDA data.
“The Company affirms its previously issued guidance: Adjusted EBITDA in the range of $12 million to $17 million.”
LifeMD plans to use a $30 million credit facility to support corporate development and shareholder value initiatives.
Newly stated in 2026-Q1. LifeMD secured a $30M credit facility to support growth initiatives. The financials do not yet reflect the utilization of this facility, indicating limited progress in capital deployment so far.
“LifeMD entered into a Credit Agreement with Citizens Bank for a $30 million credit facility.”
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. CFO Resignation On March 16, 2026, LifeMD, Inc (“LifeMD” or the “Company”) announced that its Chief Financial Officer Marc Benathen will be departing LifeMD to pursue a new opportunity. Mr. Benathen will remain employed with LifeMD through March 31, 2026, to facilitate a smooth transition in the CFO role. In connection with this transition, the Com…
Results of Operations and Financial Condition. On March 9, 2026, LifeMD, Inc. (the “Company”) issued a press release announcing its financial results for the three months and year ended December 31, 2025, and its earnings guidance for 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
Entry into a Material Definitive Agreement. On January 2, 2026, LifeMD, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with Citizens Bank, N.A. (the “Lender”), which provides for a senior secured revolving credit facility in an aggregate outstanding amount not exceeding $30 million (the “Credit Facility”) to support potential corporate development and/or shareholder value creation initiatives. The Credit Facility may be increased in the aggregate principal amoun…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in
“For the full year 2026, the Company expects: Adjusted EBITDA in the range of $12 million to $17 million.”
“For the full year 2025, the Company’s guidance reflects... adjusted EBITDA in the range of $13.5 million to $14.5 million.”